Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Platinum-resistant Recurrent Ovarian Cancer × 1-dodecylpyridoxal × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 3 Breast Neoplasms 3 Multiple Myeloma 2 Stomach Neoplasms 1 Sarcoma 1 Platinum-resistant Recurrent Ovarian Cancer 1 Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1 Lymphoma, Follicular 1 Lymphoma 1 Fallopian Tube Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 2 tremelimumab 1 durvalumab 1 Paclitaxel 1 Injections 1 Docetaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04348032 2022-03-31

APPROVE

ChineseAMS

Phase 2 Unknown

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡